Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X Mutations

NCT05907304 is registered in ClinicalTrials.gov with Erasca, Inc. as lead sponsor.

NCT NCT05907304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05907304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X Mutations
Lead sponsor
Erasca, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 17, 2023
Completion date
December 31, 2026
Enrollment
86 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors